Category: News
-
New stem cell partnership for CellBank
CellBank Australia has partnered with the European Bank for induced pluripotent Stem Cells (EBiSC) to enable our Oceania-based customers to access over 950 induced pluripotent stem cell (iPSC) lines representing over 45 different diseases. This includes gene-edited iPSC cells and pre-differentiated iPSC-Neurons. For over ten years, EBiSC has worked to enhance research outcomes by providing…
-
Pilot Study Promotion – Single Cell Analytics
We are excited to announce an exclusive Pilot Study Promotion at CMRI’s Single Cell Analytics Facility! From 12th August to 30th September, you can take advantage of this unique opportunity with no minimum sample requirement and receive preliminary bioinformatic analysis. Why Participate? Discover how Single Cell Transcriptomics can elevate your research by running a single…
-
Scaling up Viral Vector Production
Our Vectorology Facility is about to start testing viral vector production using the newly acquired large capacity Reach-in 821L CO2 incubator. This incubator is fully equipped with a roller bottle system which will assist with large scale, viral vector productions. Once testing has been completed, cells for both large-scale Caesium Chloride and small-scale Iodixanol AAV productions…
-
LIM1215 cells: Casting light on metastatic colorectal cancer
This year we will be highlighting some of the cell lines from our collection, to see how they are contributing to research discoveries and clinical translation. LIM1215 is one of our most popular cell lines and was originally deposited in our collection by the Ludwig Institute for Cancer Research in Melbourne. The cell line was…
-
Disease modelling using Organoids and Single Cell Transcriptomics
Organoids are mini-organs grown in the dish using 3D differentiation systems and have been shown to be an important tool in precision and regenerative medicine, as well as drug discovery research. When combined with the power of single cell transcriptomics, which enables transcriptomic information to be measured on thousands of single cells in a complex…
-
Lipid Nanoparticles are now offered by CMRI’s Peptide Synthesis Facility
A recent publication co-authored by CMRI’s Peptide Synthesis Facility’s Dr Md Musfizur Hassan, examined how nanoparticles can be used to predict the in vivo transport and drug delivery outcomes of various nanomedicine formulations across the blood brain barrier1. Nanoparticles are small particles (1-100nm) that are used for different clinical applications as a dosage form of…
-
Proteomics and Nature Communications Publications
Dr Mark Graham, Research Facility Lead for the Biomedical Proteomics Facility, was an author on a publication looking at the molecular changes that occur in ageing brains that was published in Proteomics. Read more: https://pubmed.ncbi.nlm.nih.gov/38115172/ He also contributed to a Nature Communications paper showing how a large-scale activity-dependent phosphoproteome analysis of hippocampal neurons in vitro and helped identify involvement of Tau in…
-
Cutting Edge Chemistry
Dr Md Musfizur Hassan, Research Facility Lead for the Peptide Synthesis Facility, was first author on a paper published in Pharmaceutics in 2023, entitled Liposome-Micelle-Hybrid (LMH) Carriers for Controlled Co-Delivery of 5-FU and Paclitaxel as Chemotherapeutics – PubMed (nih.gov) Hassan also shared his latest research when he attended the IPS 2023 13th International Peptide Symposium/15th Australian Peptide…
-
Working Towards Better Drug Delivery Systems for Chemotherapeutics
Working Towards Better Drug Delivery Systems for Chemotherapeutics A recent investigation by CMRI’s Peptide Facility Lead, Dr. Md Musfizur Hassan (1st author) and his collaborators at University of New South Wales and University of South Australia, explored the use of liposome-micelle-hybrid (LMH) carriers to enhance the delivery of the clinically relevant chemotherapeutics Paclitaxel (PTX) and…
-
Stem Cell and Organoid Facility benefits from Biorobotics upgrades
Stem Cell and Organoid Facility benefits from Biorobotics upgrades Biorobotics equipment purchases have been proceeding throughout this year ahead of a planned redevelopment for early next year that will enable the Stem Cell Medicine Group to develop Goods Manufacturing Process (GMP) protocols. This started with the purchase of the Hamilton STAR liquid handling platform in…